For 17 years, the Prevent Cancer Foundation has believed in the importance of advancing the field of quantitative CT imaging to detect and manage early thoracic disease. To demonstrate our commitment to making this Workshop as widely available as possible, the Foundation, in partnership with the American Lung Association and the Workshop sponsors (the American Cancer Society/ National Lung Cancer Roundtable, Early Diagnosis and Treatment Research Foundation on behalf of the Initiative for Early Lung Cancer Research on Treatment (IELCART), AstraZeneca, Genentech, Helsinn and GO2 Foundation) are making the Workshop available without charge to anyone who would like to register.
Quantitative Imaging Workshop XVII is a high-impact multi-disciplinary forum for the advancement of quantitative low-dose computerized tomography (LDCT) imaging biomarkers for detection and management of early thoracic disease—lung cancer, COPD and cardiovascular disease—three of the top four leading causes of death in the U.S. Now, amidst the COVID-19 pandemic, we approach this year’s Workshop with a sense of urgency.
Since 2004, the Prevent Cancer Foundation® has convened a series of annual Workshops to exchange ideas on exciting new biomedical opportunities that this transformational technology enables as well as information on the quality and consistency of policy and advocacy for responsible lung cancer, COPD and cardiovascular screening.
For the first time in 17 years, the Workshop will be held virtually, allowing for even greater global participation from oncologists, pulmonologists, surgeons, radiologists, cardiologists and imaging scientists, along with representatives of federal agencies, the pharmaceutical and imaging industries and patient advocates.
Rapid advances in medical imaging allow us to explore more accurate characterization of the clinical aggressiveness of early thoracic disease using computational analysis of high-quality thoracic CT images. This year’s Workshop will include: